SRPT — Sarepta Therapeutics, Inc.

Summary of Sarepta Therapeutics Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $2.2 billion for 2025, a 16% increase year-over-year.
• Net Product Revenue: $1.86 billion, with $966 million from PMOs and $899 million from ELEVIDYS.
• Q4 Net Product Revenue: $259 million from PMOs and $110 million from ELEVIDYS, impacted by a severe flu season and rescheduled infusions.
• Cash Position: Ended 2025 with $954 million in cash and investments, up $89 million in Q4.
• Operating Loss: GAAP operating loss of $700 million; non-GAAP operating loss of $492 million.
• Guidance for 2026: Net product revenue expected between $1.2 billion and $1.4 billion, with a flat to 15% decline anticipated in Q1.

2. Strategic Updates and Business Highlights

• Therapies: Four approved therapies, with PMOs maintaining stable demand despite some cannibalization from ELEVIDYS.
• ELEVIDYS Update: Traditional approval for ambulatory patients achieved; ongoing efforts to address safety concerns and educate physicians and patients.
• Pipeline Development: Advancements in siRNA programs targeting DM1, FSHD, IPF, and Huntington's disease, with several clinical updates expected in 2026.
• New Initiatives: Plans to enhance educational outreach and address information deficits regarding ELEVIDYS to increase patient and physician engagement.

3. Forward Guidance and Outlook

• Revenue Expectations: Guidance of $1.2 billion to $1.4 billion for 2026, with potential for higher revenue if educational initiatives yield quicker results.
• Q1 Outlook: Anticipated revenue flat to down 15% from Q4 2025, influenced by delayed patient infusions.
• Long-Term Confidence: Strong belief in the demand for ELEVIDYS and its transformative potential, with expectations for improved margins and cash flow in 2026.

4. Bad News, Challenges, or Points of Concern

• ELEVIDYS Challenges: Previous safety events have created hesitancy among patients and physicians; educational efforts are needed to restore confidence.
• Q4 Performance: Decline in ELEVIDYS revenue due to external factors, including a flu season and rescheduled infusions, impacting patient starts.
• Competitive Pressures: Potential competition from emerging exon-skipping therapies, particularly from Dyne Therapeutics, could affect PMO market share.
• Operational Risks: The long cycle time for patient enrollment and infusion could delay revenue realization from new educational initiatives.

5. Notable Q&A Insights

• CEO Transition: Doug Ingram announced plans to retire by the end of 2026, citing family commitments and personal connections to muscular dystrophy.
• ELEVIDYS Messaging: Emphasis on the need for clear communication of the therapy's benefits and risks, with metrics such as enrollment forms and infusion rates being key indicators of success.
• Market Dynamics: Discussion on the impact of newborn screening for DMD on future demand, emphasizing the need for educational efforts to reach diverse patient populations.
• Cohort 8 Recruitment: Significant interest in the ENDEAVOR trial, with expectations to present data by the end of 2026.

This summary encapsulates the key points discussed during the earnings call, highlighting Sarepta's financial performance, strategic direction, challenges, and future outlook.